がん診断における人工知能市場- 世界の産業規模、シェア、動向、機会、予測、技術別、がんタイプ別、エンドユーザー別、地域別、競合別、2020-2030年

がん診断における人工知能の世界市場は、2024年に1億2,847万米ドルと評価され、予測期間中のCAGRは8.54%で、2030年には2億862万米ドルに達し、大きく成長すると予測されています。

AIは、画像スキャンやゲノムプロファイルなどの複雑な医療データの分析を通じて、より迅速で正確な悪性腫瘍の発見を可能にすることで、がん診断に変革をもたらしつつあります。がんの罹患率が世界的に上昇する中、臨床転帰を向上させる早期発見ツールの需要が加速しています。AIを搭載した診断プラットフォームは、従来の手法では見落とされがちなデータ内の微妙なパターンを特定し、診断時間と人為的ミスを減らしながら精度を向上させることができます。これは、乳がん、肺がん、大腸がんなどの負担の大きいがんに特に有用であることが証明されています。技術の進歩、がん罹患率の増加、精密医療への強い後押しが、市場拡大の主な要因です。さらに、DELFIの肝臓がんAI血液検査のような成功したアプリケーションは、早期診断と長期生存を改善するAIの可能性を強調しています。

市場促進要因

がん罹患率の上昇と早期発見への需要が世界のがん診断における人工知能市場を牽引

主な市場課題

データの質と量が市場拡大の大きな障害に

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のがん診断における人工知能市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • テクノロジー別（ソフトウェアソリューション、ハードウェア、サービス）
  • がんの種類別（乳がん、肺がん、前立腺がん、大腸がん、脳腫瘍、その他）
  • エンドユーザー別（病院、外科センター、医療機関、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のがん診断における人工知能市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のがん診断における人工知能市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のがん診断における人工知能市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のがん診断における人工知能市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのがん診断における人工知能市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• ドライバ
• 課題

第12章 市場動向と発展

第13章 世界のがん診断における人工知能市場：SWOT分析

第14章 競合情勢

• Medial EarlySign
• Cancer Center.ai
• Microsoft Corporation
• Flatiron Health
• Path AI
• Therapixel
• Tempus Labs, Inc.
• Paige AI, Inc.
• Kheiron Medical Technologies Limited
• SkinVision

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Artificial Intelligence in Cancer Diagnostics Market was valued at USD 128.47 million in 2024 and is projected to grow significantly, reaching USD 208.62 million by 2030 with a CAGR of 8.54% during the forecast period. AI is transforming cancer diagnostics by enabling faster, more accurate detection of malignancies through the analysis of complex medical data such as imaging scans and genomic profiles. As cancer incidence rises globally, the demand for early detection tools that enhance clinical outcomes is accelerating. AI-powered diagnostic platforms can identify subtle patterns in data that might elude traditional methods, improving accuracy while reducing diagnostic time and human error. This has proven particularly valuable for high-burden cancers like breast, lung, and colorectal cancer. Technological advancements, increasing cancer prevalence, and a strong push for precision medicine are key factors driving market expansion. Moreover, successful applications such as DELFI's AI blood test for liver cancer highlight the potential of AI to improve early-stage diagnosis and long-term survival.

Key Market Drivers

Rising Cancer Incidence and Demand for Early Detection is Driving the Global Artificial Intelligence In Cancer Diagnostics Market

With cancer remaining a leading cause of death globally, early detection has become a top priority in healthcare systems. The growing incidence of cancer-attributed to aging populations, lifestyle factors, and environmental exposure-is driving demand for diagnostic tools that can catch tumors at their earliest and most treatable stages. AI is emerging as a game-changing technology in this regard. By analyzing extensive patient data, including radiologic and pathologic images, AI systems help clinicians identify malignancies faster and more accurately. For example, the American Cancer Society estimates over 2 million new cancer cases in the U.S. alone for 2024, underscoring the urgency for efficient diagnostic solutions. AI's ability to support rapid analysis and generate diagnostic insights across multiple cancer types enhances its value proposition, especially as healthcare providers seek scalable tools to meet increasing patient volumes and complexity in diagnostics.

Key Market Challenges

Data Quality and Quantity Poses a Significant Obstacle To Market Expansion

AI models require large, high-quality datasets to perform accurately and generalize effectively across populations. However, in cancer diagnostics, data availability and standardization remain significant hurdles. Variations in imaging protocols, inconsistent data labeling, and fragmented electronic health records can affect model training and limit diagnostic precision. Additionally, privacy concerns and regulatory barriers often restrict data sharing between institutions, limiting access to comprehensive datasets. These challenges slow the development of robust AI solutions and delay their clinical validation and deployment. Addressing this issue requires cross-institutional collaboration, anonymized data sharing frameworks, and rigorous data governance policies.

Key Market Trends

Technological Advancements

AI continues to advance rapidly, especially in areas such as machine learning, computer vision, and natural language processing. In cancer diagnostics, these technologies are enhancing image analysis, pathology workflows, and genomic profiling. AI algorithms now assist in detecting abnormalities in imaging scans with high precision, identifying early-stage tumors, and predicting treatment responses based on patient-specific genetic information. For instance, AI tools can detect textural or morphological changes in tissues that indicate early malignancies, which may not be visible to the human eye. Additionally, AI supports precision oncology by analyzing genomic mutations to match patients with targeted therapies. These technological innovations are improving diagnostic accuracy, reducing diagnostic delays, and enabling personalized treatment planning. As integration with clinical systems becomes more seamless, AI adoption in oncology diagnostics is expected to scale rapidly across healthcare institutions globally.

Key Market Players

• Medial EarlySign
• Cancer Center.ai
• Microsoft Corporation
• Flatiron Health
• Path AI
• Therapixel
• Tempus Labs, Inc.
• Paige AI, Inc.
• Kheiron Medical Technologies Limited
• SkinVision

Report Scope:

In this report, the Global Artificial Intelligence In Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Intelligence In Cancer Diagnostics Market, By Technology:

• Software Solutions
• Hardware
• Services

Artificial Intelligence In Cancer Diagnostics Market, By Cancer Type:

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Brain Tumor
• Others

Artificial Intelligence In Cancer Diagnostics Market, By End User:

• Hospital
• Surgical Centres and Medical Institutes
• Others

Artificial Intelligence In Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence In Cancer Diagnostics Market.

Available Customizations:

Global Artificial Intelligence In Cancer Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Global Artificial Intelligence In Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Software Solutions, Hardware, Services)
  • 5.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
  • 5.2.3. By End-User (Hospital, Surgical Centers and Medical Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Artificial Intelligence In Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Cancer Type
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Cancer Type
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Cancer Type
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Cancer Type
      • 6.3.3.2.3. By End-User

7. Europe Artificial Intelligence In Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Cancer Type
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Cancer Type
      • 7.3.1.2.3. By End-User
  • 7.3.2. United Kingdom Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Cancer Type
      • 7.3.2.2.3. By End-User
  • 7.3.3. Italy Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Cancer Type
      • 7.3.3.2.3. By End-User
  • 7.3.4. France Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Cancer Type
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Cancer Type
      • 7.3.5.2.3. By End-User

8. Asia-Pacific Artificial Intelligence In Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Cancer Type
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Cancer Type
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Cancer Type
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Cancer Type
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Cancer Type
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Cancer Type
      • 8.3.5.2.3. By End-User

9. South America Artificial Intelligence In Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Cancer Type
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Cancer Type
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Cancer Type
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Cancer Type
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Artificial Intelligence In Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Cancer Type
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Cancer Type
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Cancer Type
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Cancer Type
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Driver
• 11.2. Challenges

12. Market Trends & Developments

13. Global Artificial Intelligence In Cancer Diagnostics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Medial EarlySign
  • 14.1.1. Business Overview
  • 14.1.2. Cancer Type Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. Cancer Center.ai
• 14.3. Microsoft Corporation
• 14.4. Flatiron Health
• 14.5. Path AI
• 14.6. Therapixel
• 14.7. Tempus Labs, Inc.
• 14.8. Paige AI, Inc.
• 14.9. Kheiron Medical Technologies Limited
• 14.10. SkinVision

15. Strategic Recommendations

16. About Us & Disclaimer